Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer

by Venkannagari, Sreedhar, Fiskus, Warren, Peth, Karissa, Atadja, Peter, Hidalgo, Manuel, Maitra, Anirban, Bhalla, Kapil N.
Published 2012

HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist

by Devaraj, Santhana G. T., Fiskus, Warren, Shah, Bhavin, Qi, Jun, Sun, Baohua, Iyer, Swaminathan P, Sharma, Sunil, Bradner, James E., Bhalla, Kapil N.
Published 2015

Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells

by Fiskus, Warren, Sharma, Sunil, Saha, Saikat, Shah, Bhavin, Devaraj, Santhana G. T., Sun, Baohua, Horrigan, Stephen, Leveque, Christopher, Zu, Youli, Iyer, Swaminathan, Bhalla, Kapil N.
Published 2014

Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells

by Fiskus, Warren, Sharma, Sunil, Shah, Bhavin, Portier, Bryce P., Devaraj, Santhana G. T., Liu, Ka, Iyer, Swaminathan P., Bearss, David, Bhalla, Kapil N.
Published 2014

Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells

by Ha, Kyungsoo, Fiskus, Warren, Choi, Dong Soon, Bhaskara, Srividya, Cerchietti, Leandro, Devaraj, Santhana G. T., Shah, Bhavin, Sharma, Sunil, Chang, Jenny C., Melnick, Ari M., Hiebert, Scott, Bhalla, Kapil N.
Published 2014